cyclic-gmp and etofibrate

The effect of several anti-atherogenic drugs (ticlopidine, nicotinic acid and etofibrate) on immune responses and immune complex anaphylaxis has been studied in mice. All the drugs enhanced the activation by concanavalin A, phytohemagglutinin, and lipopolysaccharide of lymphocytes taken from treated animals. Contact hypersensitivity to trinitrochlorobenzene was inhibited by similar treatments with the same drugs, possibly through inhibition of the efferent phase of the reaction. Nicotinic acid produced a slight enhancement of antibody responses to sheep erythrocytes, whereas etofibrate inhibited the response at the highest dose studied. In addition, treatment with these drugs variably protected the mice from anaphylactic shocks induced by immune complexes. Marked protection was also observed using the antiserotoninic, cyproheptadine. These results indicate that drugs used to prevent atherogenic processes modulate different proliferative and effector immunological reactions.

Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Niacin; Thiophenes; Ticlopidine

Topics: Adipose Tissue; Animals; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; In Vitro Techniques; Insulin; Liver; Male; Nicotinic Acids; Protein Binding; Protein Kinases; Rats